Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Coronary stenting is a common procedure to treat coronary artery disease.
• Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard post-stenting.
• Optimizing DAPT duration and safety is crucial for patient outcomes.

Purpose of the Study:

• To evaluate the safety and efficacy of a 2-week clopidogrel and aspirin regimen after coronary stenting.
• To assess the incidence of in-hospital death, stent thrombosis, and other adverse events at 30-day follow-up.

Main Methods:

• A prospective study of 250 consecutive patients undergoing coronary stenting.
• Patients received a 150 mg loading dose of clopidogrel followed by 75 mg daily for 2 weeks, along with aspirin.
• Outcomes including mortality, stent thrombosis (acute and subacute), myocardial infarction, and repeat interventions were recorded at 30 days.

Main Results:

• A very low in-hospital mortality rate of 0.4% (1 patient).
• Low rates of acute (0.4%) and subacute (0.8%) stent thrombosis.
• No Q-wave myocardial infarctions, vascular complications, or repeat interventions were observed within 30 days.

Conclusions:

• A 2-week course of clopidogrel and aspirin following coronary stenting is associated with a low risk of major adverse cardiovascular events.
• This short-term DAPT regimen appears safe and effective in the early period after coronary stenting.
• Further research may explore longer-term outcomes with this regimen.